Kevin Charles Gorman

Director

Kevin Charles Gorman (Director) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Neurocrine Biosciences, Inc. (NBIX). The largest single filing was $37.8M of NBIX (245,088 sh × $154.33, as filed), executed May 19.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 1 sells

Median delay

–

execution → disclosure

Volume, ttmiDollar value disclosed in the trailing twelve months

$37.8M

shares × price, as filed

Last traded

May 19

Filed May 21

Median ADV $194.2M across their filed names

Open performance→

Volume by month

Buys $0 Sells $75.6M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 1 filing

Sector per market data · by filing · past 12 months

Most traded names

NBIX Neurocrine Biosciences, Inc. NBIX · 0 buys · 7 sells 7 filings

Recent filings

NBIXSALE Neurocrine Biosciences, Inc. View filing → $37.8M
245,088 sh × $154.33
Exec May 19
Filed May 21 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $13.4M
106,322 sh × $126.41
Exec Aug 7 2025
Filed Aug 11 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $1.2M
9,613 sh × $120.38
Exec May 27 2025
Filed May 29 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $682K
5,844 sh across 2 lots
Exec Feb 13 2025
Filed Feb 14 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $269K
2,274 sh × $118.37
Exec Feb 10 2025
Filed Feb 12 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $414K
2,707 sh × $152.92
Exec Jan 31 2025
Filed Feb 4 2025 · 5:30 PM ET NBIXSALE Neurocrine Biosciences, Inc. View filing → $21.8M
146,105 sh × $149.46
Exec Jan 27 2025
Filed Jan 29 2025 · 5:30 PM ET